Nuzenio

Sensitive Prostate Cancer

Sensitive Prostate Cancer news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 18 latest news signals 15 publisher sources 100/100 entity strength

Latest news

Published data show rPFS benefit with lutetium Lu 177 vipivotide tetraxetan in mHSPC - Urology TimesUrology Times · Sat, 08 Aug 2026 17:49:18 GMT FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease - NovartisNovartis · Sat, 08 Aug 2026 12:24:46 GMT Caris Life Sciences Launches PTEN IHC Testing for Prostate Cancer - Clinical Lab ProductsClinical Lab Products · Fri, 07 Aug 2026 13:15:14 GMT Approval of Pluvicto® for Metastatic Hormone-Sensitive Prostate Cancer - Oliver Sartor - UroTodayUroToday · Thu, 06 Aug 2026 19:44:56 GMT CAPItello-281 and the PTEN-Deficient Subset of Metastatic Hormone-Sensitive Prostate Cancer - Alicia Morgans - UroTodayUroToday · Thu, 06 Aug 2026 17:23:13 GMT HRR-Altered Metastatic Prostate Cancer Talazoparib Plus Enzalutamide Improves Progression-Free Survival - The ASCO PostThe ASCO Post · Thu, 06 Aug 2026 14:00:43 GMT Alan Bryce, MD, highlights key phase 3 advances in prostate cancer - Urology TimesUrology Times · Tue, 04 Aug 2026 17:02:54 GMT FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer - The American Journal of Managed Care® (AJMC®)The American Journal of Managed Care® (AJMC®) · Mon, 03 Aug 2026 17:37:08 GMT

Timeline

Sat, 08 Aug 2026 17:49:18 GMTPublished data show rPFS benefit with lutetium Lu 177 vipivotide tetraxetan in mHSPC - Urology Times

Sat, 08 Aug 2026 12:24:46 GMTFDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease - Novartis

Fri, 07 Aug 2026 13:15:14 GMTCaris Life Sciences Launches PTEN IHC Testing for Prostate Cancer - Clinical Lab Products

Thu, 06 Aug 2026 19:44:56 GMTApproval of Pluvicto® for Metastatic Hormone-Sensitive Prostate Cancer - Oliver Sartor - UroToday

Thu, 06 Aug 2026 17:23:13 GMTCAPItello-281 and the PTEN-Deficient Subset of Metastatic Hormone-Sensitive Prostate Cancer - Alicia Morgans - UroToday

Thu, 06 Aug 2026 14:00:43 GMTHRR-Altered Metastatic Prostate Cancer Talazoparib Plus Enzalutamide Improves Progression-Free Survival - The ASCO Post

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.

Connected entities

Pluvicto16 live mentions Metastatic Hormone6 live mentions FDA5 live mentions FDA Approves Lutetium4 live mentions HRR3 live mentions Earlier3 live mentions The American Journal3 live mentions Managed Care3 live mentions AJMC3 live mentions Novartis3 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Sensitive Prostate Cancer.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

15 distinct publisher/source names are currently connected to this entity page.